Uskalí lécby perorálními antidiabetiky
[Pitfalls in treatment with oral antidiabetic agents]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
9750481
- MeSH
- Acarbose MeSH
- Administration, Oral MeSH
- Biguanides administration & dosage adverse effects MeSH
- Diabetes Mellitus, Type 2 drug therapy MeSH
- Hypoglycemic Agents administration & dosage adverse effects MeSH
- Humans MeSH
- Sulfonylurea Compounds administration & dosage adverse effects MeSH
- Trisaccharides administration & dosage adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Acarbose MeSH
- Biguanides MeSH
- Hypoglycemic Agents MeSH
- Sulfonylurea Compounds MeSH
- Trisaccharides MeSH
In the treatment of type 2 diabetes (NIDDM) we possess three groups of oral hypoglycaemic drugs: sulfonyl urea derivatives, biguanides (metformin) and alpha-glucosidase (acarbose) inhibitors. Oral treatment of diabetes has a favourable impact on the patients metabolic deviations but it involves also certain dangers and pitfalls. The side-effects of oral antidiabetics can be reduced to a minimum by respecting consequentially contraindications of administration of different preparations, knowledge of their mechanism of action and individual selection of a suitable antidiabetic for every patient.
